Showing results (1-10 of 47) with videos related to
Sort By:
Pageof 5
Neurologic Clinics|March 29, 2011
Treatment of multiple sclerosis exacerbationsPavle Repovic, Fred D LublinThe Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 5, 2002
Prostaglandin E2 is a novel inducer of oncostatin-M expression in macrophages and microgliaPavle Repovic, Etty N BenvenisteGlia|May 6, 2003
Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharidePavle Repovic, Kaihong Mi, Etty N BenvenisteInternational Journal of MS Care|July 25, 2022
Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future DirectionsBianca Weinstock-Guttman, Maria Pia Sormani, Pavle RepovicNeurology and Therapy|January 23, 2022
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19Robert K Shin, Pavle Repovic, Joseph R BergerOncogene|November 7, 2003
Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cellsPavle Repovic, Constance Y Fears, Candece L Gladson, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 15, 2023
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, et al.Clinical Therapeutics|November 25, 2018
Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational StudyKiren Kresa-Reahl, Pavle Repovic, Derrick Robertson, et al.Neurology|October 27, 2020
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple SclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Pageof 5